Abstract: Embodiments of the present invention relate generally to non-invasive methods and tests that measure biomarkers (e.g., tumor antigens) and collect clinical parameters from patients, and computer-implemented machine learning methods, apparatuses, systems, and computer-readable media for assessing a likelihood that a patient has a disease, relative to a patient population or a cohort population. In one embodiment, a classifier is generated using a machine learning system based on training data from retrospective data and subset of inputs (e.g. at least two biomarkers and at least one clinical parameter), wherein each input has an associated weight and the classifier meets a predetermined Receiver Operator Characteristic (ROC) statistic, specifying a sensitivity and a specificity, for correct classification of patients.

Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.

Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.

Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.

Abstract: The invention relates to methods and preparations for sorting out T effector cells from human leukocytes using anti-CD127 antibodies. Accordingly the invention relates to the use of anti-CD127 antibodies enabling discriminative depletion of subpopulations of Tregulatory cells expressing CD127+ at low levels in a population of human T lymphocytes in order to enable the use of the recovered selected cell preparations comprising essentially Teffector cells as lymphocytes and preferably devoid of Tregulatory cells, for improved efficacy in particular when administered to a patient for therapy.

Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.

Abstract: The present invention relates methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.

Abstract: The present invention relates to methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.

Abstract: The invention relates to the use of allogenic T lymphocytes for the preparation of a composition intended to be injected into a recipient patient as a conditioning for a transplantation of haematopoietic stem cells, said allogenic T lymphocytes expressing a molecule allowing their specific destruction.

Abstract: The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment.

Abstract: The present invention discloses a mechanical embolectomy device for the removal of intravascular embolic material, especially blood clots. The device comprises of a microcatheter of dimensions suitable for introduction into a blood vessel; a microguide wire; and a retriever coil attached to the distal end of said microcatheter; said retriever coil is positioned to dislodge and remove said embolic material from said blood vessel. A method for removing of intravascular embolic materials is also disclosed.

Abstract: The present invention relates to the fields of biology, genetics and medicine. The invention discloses methods and compositions for treating various diseases using populations or compositions of immunoregulatory T cells. The invention discloses that regulatory T cells may be produced and used to control in vivo various pathological conditions, including diseases associated with abnormal T cell activity. The invention relates to the manufacture of such regulatory T cell compositions as well as to their uses for cell therapy treatment. The invention is particularly suited for controlling graft versus host disease in subjects undergoing transplantation (e.g., bone marrow transplantation).

Abstract: A postural bra for supporting and protecting a woman's breasts, helps prevent and correct a tendency of hyperkyphosis of the backbone. The postural bra comprises a bra body (12), provided in its central front part with vertical shoulder lifters (14A, 14B) and of a posterior support (16). The bra body contains, in its lateral edges, identical straps (18A, 18B) which are connected at one of their edges, to upper parts of the vertical folds (20A, 20B) of the referred posterior support (16) and, in the other edges, to the lower parts of the horizontal folds (22A, 22B) of the referred posterior support (16), from which point adjusting straps (24A, 24B) are lengthened.